AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38743040 — intervention group
Group type: EXPERIMENTAL
Intervention: Major complications (Clavien-Dindo grade at least IIIa)
Number of subjects: 4223
Study 38743155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab (200 mg for body weight ≥ 5 kg to < 15 kg; 300 mg for body weight ≥ 15 kg to < 30 kg) every 4 weeks for 1 year
Number of subjects: 142
Study 38743155 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 142
Study 38743248 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment for periodontitis
Number of subjects: 45
Study 38743248 — intervention group
Group type: COMPARATOR
Intervention: Periodontitis
Number of subjects: 45
Study 38743248 — intervention group
Group type: COMPARATOR
Intervention: Healthy control
Number of subjects: 45
Study 38743248 — intervention group
Group type: COMPARATOR
Intervention: Gingivitis
Number of subjects: 45
Study 38743248 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for Galectin-1
Number of subjects: 45
Study 38743248 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC analysis for Galectin-3
Number of subjects: 45
Study 38743265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 8 weekly sessions
Number of subjects: 16
Study 38743265 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-Body Hyperthermia (WBH) - 8 weekly sessions
Number of subjects: 16
Study 38743265 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) and Whole-Body Hyperthermia (WBH) combined
Number of subjects: 16
Study 38743288 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly high-dose vitamin D supplementation
Number of subjects: 0
Study 38743388 — intervention group
Group type: EXPERIMENTAL
Intervention: EthioPerm (Permanent ostomy patients in Ethiopia)
Number of subjects: 66
Study 38743388 — intervention group
Group type: EXPERIMENTAL
Intervention: EthioTemp (Temporary ostomy patients in Ethiopia)
Number of subjects: 66
Study 38743388 — intervention group
Group type: COMPARATOR
Intervention: SweSto (Ostomy patients in Sweden)
Number of subjects: 66
Study 38743388 — intervention group
Group type: EXPERIMENTAL
Intervention: EthioPerm
Number of subjects: 66
Study 38743388 — intervention group
Group type: COMPARATOR
Intervention: SweSto
Number of subjects: 66
Study 38743423 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (CTD)
Number of subjects: 13523
Study 38743423 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 13523
Study 38743473 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiagnostic CBT
Number of subjects: 150
Study 38743473 — intervention group
Group type: COMPARATOR
Intervention: WAIT (Waitlist)
Number of subjects: 150
Study 38743564 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-xenon UV (PX-UV) disinfection after standard terminal cleaning
Number of subjects: 25732
Study 38743564 — intervention group
Group type: COMPARATOR
Intervention: Sham disinfection (control)
Number of subjects: 25732
Study 38743692 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent inactivated vaccine (TIV)
Number of subjects: 283
Study 38743692 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing ADCP scores ≥250
Number of subjects: 283
Study 38743692 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCD scores of ≥25
Number of subjects: 283
Study 38743692 — intervention group
Group type: EXPERIMENTAL
Intervention: ADCD scores of ≥15
Number of subjects: 283
Study 38743692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 38743716 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 460
Study 38743716 — intervention group
Group type: COMPARATOR
Intervention: Prison treatment as usual (Control)
Number of subjects: 460
Study 38743727 — intervention group
Group type: EXPERIMENTAL
Intervention: After-discharge complete revascularization (CR)
Number of subjects: 258
Study 38743727 — intervention group
Group type: COMPARATOR
Intervention: In-hospital complete revascularization (CR)
Number of subjects: 258
Study 38743939 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive Virtual Reality intervention for preoperative anxiety (PSA)
Number of subjects: 0
Study 38743939 — intervention group
Group type: COMPARATOR
Intervention: VR control (nature trek)
Number of subjects: 0
Study 38743939 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual group
Number of subjects: 0
Study 38743958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age-based dosing of UFH (5,000 units subcutaneously every 12 hours in first trimester; 7,500 units in second trimester; 10,000 units in third trimester)
Number of subjects: 46
Study 38743958 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of UFH (5,000 units subcutaneously every 12 hours)
Number of subjects: 46
Study 38743958 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational age-based dosing of UFH
Number of subjects: 46
Study 38743958 — intervention group
Group type: COMPARATOR
Intervention: Standard dosing of UFH
Number of subjects: 46
Study 38744144 — intervention group
Group type: EXPERIMENTAL
Intervention: Quizartinib (30 mg, 40 mg, or 60 mg) in combination with azacitidine
Number of subjects: 12
Study 38744428 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless Feedback System (WFS)
Number of subjects: 400
Study 38744428 — intervention group
Group type: COMPARATOR
Intervention: WFS plus coaching
Number of subjects: 400
Study 38744428 — intervention group
Group type: COMPARATOR
Intervention: WFS vs WFS plus coaching
Number of subjects: 400
Study 38744428 — intervention group
Group type: COMPARATOR
Intervention: Modest vs vigorous step-up interventions among nonresponders
Number of subjects: 400
Study 38744460 — intervention group
Group type: EXPERIMENTAL
Intervention: First Disease-Modifying Therapy (DMT)
Number of subjects: 1587
Study 38744460 — intervention group
Group type: EXPERIMENTAL
Intervention: DMT Switch
Number of subjects: 1587
Study 38744460 — intervention group
Group type: EXPERIMENTAL
Intervention: First DMT
Number of subjects: 1587
Study 38744598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in Arm A1 (n = 361)
Number of subjects: 465
Study 38744598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in hybrid-immunity subgroup (Arm A1)
Number of subjects: 465
Study 38744598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in Arm A2 (n = 104)
Number of subjects: 465
Study 38744598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S booster in ≥ 60-year-olds
Number of subjects: 465
Study 38744750 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (I)
Number of subjects: 205
Study 38744750 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (C)
Number of subjects: 205
Study 38744792 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase-locked acoustic stimulation (PLAS)
Number of subjects: 18
Study 38744792 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 18
Study 38744804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepiz One + device
Number of subjects: 141
Study 38744804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepiz One +  device with additional SpO2 information
Number of subjects: 141
Study 38744804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleepiz One +  device without additional SpO2 information
Number of subjects: 141
Study 38744804 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 141
Study 38744844 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCT-154 vaccine (two doses, 28 days apart)
Number of subjects: 0
Study 38744844 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCT-154 vaccine
Number of subjects: 0
Study 38744844 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0
Study 38744929 — intervention group
Group type: EXPERIMENTAL
Intervention: restricted diet including calorie restriction, hot water drinking, walking, and sexual self-restraint
Number of subjects: 70
Study 38745011 — intervention group
Group type: EXPERIMENTAL
Intervention: PR006 gene therapy
Number of subjects: 13
Study 38745158 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated transdiagnostic and micro choice-based group treatment
Number of subjects: 67
Study 38745175 — intervention group
Group type: EXPERIMENTAL
Intervention: Remimazolam
Number of subjects: 55
Study 38745176 — intervention group
Group type: EXPERIMENTAL
Intervention: Dance intervention program (1 hour of online dance classes per week for 10 weeks)
Number of subjects: 43
Study 38745176 — intervention group
Group type: COMPARATOR
Intervention: Control group (10-week waiting period)
Number of subjects: 43
Study 38745227 — intervention group
Group type: EXPERIMENTAL
Intervention: Task-oriented training assisted by a force feedback rehabilitation robot for 20 min/day
Number of subjects: 44
Study 38745227 — intervention group
Group type: COMPARATOR
Intervention: Conventional task-oriented training assisted by therapists for 20 min/day
Number of subjects: 44
Study 38745260 — intervention group
Group type: EXPERIMENTAL
Intervention: GGED-AD app used for 14 consecutive days for approximately 5 minutes each day.
Number of subjects: 0
Study 38745260 — intervention group
Group type: COMPARATOR
Intervention: GGNEUTRAL app used for 14 consecutive days for approximately 5 minutes each day.
Number of subjects: 0
Study 38745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bond Universal by 3 M ESPE
Number of subjects: 105
Study 38745306 — intervention group
Group type: EXPERIMENTAL
Intervention: Xeno-V+ by Dentsply
Number of subjects: 105
Study 38745306 — intervention group
Group type: COMPARATOR
Intervention: Bifluorid 12 by Voco (Control)
Number of subjects: 105
Study 38745312 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal agency-based training for women (2 days) and their male partners (1 day)
Number of subjects: 1061
Study 38745322 — intervention group
Group type: EXPERIMENTAL
Intervention: Video Therapy (VT)
Number of subjects: 33
Study 38745322 — intervention group
Group type: COMPARATOR
Intervention: Mirror Therapy (MT)
Number of subjects: 33
Study 38745333 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative hypofractionated proton beam therapy (PBT) - 30 Gy radiobiological equivalent in 5 fractions delivered every other day.
Number of subjects: 40
Study 38745502 — intervention group
Group type: EXPERIMENTAL
Intervention: Torsemide
Number of subjects: 2859
Study 38745502 — intervention group
Group type: COMPARATOR
Intervention: Furosemide
Number of subjects: 2859
Study 38745592 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-based weight management intervention delivered through the patient portal with primary care staff as coaches
Number of subjects: 0
Study 38745592 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation tracking metrics for IT tools
Number of subjects: 0
Study 38745592 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive multi-level implementation approach
Number of subjects: 0
Study 38745592 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive involvement of clinic leadership
Number of subjects: 0
Study 38745592 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-technical formative evaluation methods
Number of subjects: 0
Study 38745965 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-ICI-VEGF
Number of subjects: 1244
Study 38745967 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib
Number of subjects: 265
Study 38745967 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 265
Study 38745983 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of indocyanine green (ICG) fluorescence imaging
Number of subjects: 14
Study 38745983 — intervention group
Group type: COMPARATOR
Intervention: Fluorescence parameters and clinical variables
Number of subjects: 14
Study 38745998 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash incentives (up to SGD50 per month)
Number of subjects: 0
Study 38745998 — intervention group
Group type: EXPERIMENTAL
Intervention: Hedonic incentives (up to SGD50 per month)
Number of subjects: 0
Study 38746060 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Lot 1
Number of subjects: 757
Study 38746060 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Lot 2
Number of subjects: 757
Study 38746060 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA Lot 3
Number of subjects: 757
Study 38746060 — intervention group
Group type: EXPERIMENTAL
Intervention: Solicited AEs
Number of subjects: 757
Study 38746060 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsolicited AEs
Number of subjects: 757
Study 38746060 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious AEs (SAEs)
Number of subjects: 757
Study 38746060 — intervention group
Group type: EXPERIMENTAL
Intervention: SAEs with fatal outcome
Number of subjects: 757
Study 38746125 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal, digitally enhanced intervention including a smartwatch, study app, mobile integrated health program, and virtual pulmonary support service.
Number of subjects: 100
Study 38746205 — intervention group
Group type: EXPERIMENTAL
Intervention: TELESCOPE intervention: telehealth decision coaching session about LCS delivered by trained patient navigators, with a low-dose CT scan (LDCT) order placed for each patient wanting LCS.
Number of subjects: 420
Study 38746205 — intervention group
Group type: EXPERIMENTAL
Intervention: TELESCOPE intervention: telehealth decision coaching booster session with a navigator for patients whose initial LCS showed low-risk findings.
Number of subjects: 420
Study 38746205 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC): patients receive enhanced usual care from a clinician, with access to a Continuing Medical Education (CME) webinar about LCS and an LCS discussion guide.
Number of subjects: 420
Study 38746210 — intervention group
Group type: EXPERIMENTAL
Intervention: Detectable total testosterone levels in females
Number of subjects: 215
Study 38746210 — intervention group
Group type: COMPARATOR
Intervention: Undetectable total testosterone levels in females
Number of subjects: 215
Study 38746215 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (bis-octanoyl (R)-1,3-butanediol)
Number of subjects: 30
Study 38746215 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) containing canola oil
Number of subjects: 30
Study 38746220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib 800mg daily plus Gemcitabine 1000mg/m2
Number of subjects: 43
Study 38746220 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus Gemcitabine
Number of subjects: 43
Study 38746275 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 27
Study 38746275 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 27
Study 38746368 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use for medical symptoms for one year
Number of subjects: 57
Study 38746368 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (no cannabis use)
Number of subjects: 57
Study 38746428 — intervention group
Group type: EXPERIMENTAL
Intervention: Norming strategy
Number of subjects: 328
Study 38746428 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 328
Study 38746736 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling
Number of subjects: 0
Study 38746736 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based support
Number of subjects: 0
Study 38746793 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized nurse-led patient education programs focused on self-management of venous leg ulcers
Number of subjects: 0
Study 38746793 — intervention group
Group type: EXPERIMENTAL
Intervention: Constructivist Grounded Theory methodology
Number of subjects: 0
Study 38746861 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 139
Study 38746861 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 139
Study 38746989 — intervention group
Group type: COMPARATOR
Intervention: Dersimelagon 100 mg in participants with mild and moderate hepatic impairment and normal hepatic function
Number of subjects: 47
Study 38746989 — intervention group
Group type: COMPARATOR
Intervention: Dersimelagon 300 mg in participants with mild, moderate, and severe renal impairment and normal renal function
Number of subjects: 47
Study 38747162 — intervention group
Group type: EXPERIMENTAL
Intervention: NBO-2h group (10 L/min for 2 hours)
Number of subjects: 100
Study 38747162 — intervention group
Group type: EXPERIMENTAL
Intervention: NBO-4h group (10 L/min for 4 hours)
Number of subjects: 100
Study 38747162 — intervention group
Group type: EXPERIMENTAL
Intervention: NBO-6h group (10 L/min for 6 hours)
Number of subjects: 100
Study 38747162 — intervention group
Group type: COMPARATOR
Intervention: Control group (1 L/min oxygen for 4 hours)
Number of subjects: 100
Study 38747246 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI
Number of subjects: 370
Study 38747246 — intervention group
Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 370
Study 38747246 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (Tricuspid AS)
Number of subjects: 370
Study 38747246 — intervention group
Group type: COMPARATOR
Intervention: Surgery (Tricuspid AS)
Number of subjects: 370
Study 38747246 — intervention group
Group type: EXPERIMENTAL
Intervention: TAVI (Bicuspid AS)
Number of subjects: 370
Study 38747246 — intervention group
Group type: COMPARATOR
Intervention: Surgery (Bicuspid AS)
Number of subjects: 370
Study 38747414 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, lenalidomide, and dexamethasone
Number of subjects: 0
Study 38747414 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide alone
Number of subjects: 0
Study 38747515 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone Wound Healing Questionnaire (WHQ) administered at 27 to 30 postoperative days.
Number of subjects: 1196
Study 38747515 — intervention group
Group type: COMPARATOR
Intervention: In-person review by a trained clinician at 30 postoperative days.
Number of subjects: 1196
Study 38747680 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole
Number of subjects: 0
Study 38747680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 38747749 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 7000 IU/day
Number of subjects: 53
Study 38747749 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 38748236 — intervention group
Group type: EXPERIMENTAL
Intervention: TOETVA surgery
Number of subjects: 20
Study 38748271 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-[18F]FDG-PET/MRI
Number of subjects: 11
Study 38748286 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast-enhanced MRI (ce-MRI)
Number of subjects: 7
Study 38748319 — intervention group
Group type: EXPERIMENTAL
Intervention: EDP1815 (8 × 10^9 CFU daily)
Number of subjects: 36
Study 38748319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 38748321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 5 mg (LEM5)
Number of subjects: 262
Study 38748321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant 10 mg (LEM10)
Number of subjects: 262
Study 38748321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lemborexant (both doses)
Number of subjects: 262
Study 38748321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 262
Study 38748345 — intervention group
Group type: EXPERIMENTAL
Intervention: Crisaborole ointment 2%
Number of subjects: 237
Study 38748345 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 237
Study 38748431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (n=1420) including gastric banding (n=260), vertical banded gastroplasty (n=970), gastric bypass (n=190)
Number of subjects: 2867
Study 38748431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in women with baseline insulin levels above median 15.8 μIU/L
Number of subjects: 2867
Study 38748431 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in women with baseline insulin levels below median 15.8 μIU/L
Number of subjects: 2867
Study 38748431 — intervention group
Group type: COMPARATOR
Intervention: Usual obesity care (control group, n=1447)
Number of subjects: 2867
Study 38748596 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan (SG)
Number of subjects: 0
Study 38748596 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 0
Study 38748598 — intervention group
Group type: EXPERIMENTAL
Intervention: Bridging intravenous thrombolysis (IVT) before endovascular therapy (EVT)
Number of subjects: 2749
Study 38748598 — intervention group
Group type: COMPARATOR
Intervention: Direct endovascular therapy (EVT) alone
Number of subjects: 2749
Study 38748939 — intervention group
Group type: EXPERIMENTAL
Intervention: Pertuzumab plus trastuzumab
Number of subjects: 29
Study 38748986 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/lamivudine/dolutegravir (TLD)
Number of subjects: 500
Study 38749024 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week internet intervention program based on acceptance and commitment therapy principles
Number of subjects: 15
Study 38749033 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus chemotherapy
Number of subjects: 0
Study 38749033 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus placebo
Number of subjects: 0
Study 38749032 — intervention group
Group type: EXPERIMENTAL
Intervention: Andexanet
Number of subjects: 530
Study 38749032 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 530
Study 38749110 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib plus bevacizumab
Number of subjects: 309
Study 38749110 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib alone
Number of subjects: 309
Study 38749110 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus fluoropyrimidine
Number of subjects: 309
Study 38749259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine (2.5 μg/kg initial dose, 1 μg/kg repeat dose if needed 30 min later)
Number of subjects: 59
Study 38749259 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 59
Study 38749594 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent-Avoiding (SA) strategy
Number of subjects: 120